Superworth

Arrowhead Pharmaceuticals price to free cash flow ARWR

Market value divided by free cash flow over the last twelve months, since 2019.

Today, Oct 23, 2026
n/m
not a meaningful number
Last meaningful
32.5×
May 2026
8-year median
37.6×
8-year range
11.0× to 264×
Peer median
46.0×

Arrowhead Pharmaceuticals' price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in May 2026, at 32.5×.

On the days it had one over the last 8 years, its median was 37.6×, from 11.0× in Feb 2019 to 264× in Jul 2025.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far32.5×23.9×60.0×
202560.7×45.6×264×
2024n/m a value too high to mean anything
2023n/m a value too high to mean anything
202231.5×31.5×43.2×
202146.9×37.4×56.9×
202024.9×24.9×36.6×
201938.6×11.0×43.4×

Against its peers

Companies in Drug Manufacturers - General nearest Arrowhead Pharmaceuticals' size, closest first, today.

CompanyPrice to free cash flow
ARWRArrowhead Pharmaceuticalsn/m
TGTXTG Therapeutics477×
PTGXProtagonist Therapeutics68.6×
ALKSAlkermes plc.33.0×
CORTCorcept Therapeutics86.8×
AMRXAmneal Pharmaceuticals50.9×
BMRNBiomarin Pharmaceutical14.7×
LGNDLigand Pharmaceuticals46.0×
KNSAKiniksa Pharmaceuticals International32.7×
JAZZJazz Pharmaceuticals8.7×
INDVIndivior Pharmaceuticalsn/m
Peer median46.0×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Arrowhead Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.